Effect of ezetimibe/atorvastatin combination on oxidized low density lipoprotein cholesterol in patients with coronary artery disease or coronary artery disease equivalent

American Journal of Cardiology

Volumn 106, Issue 2, 2010, Pages 193-197

  Azar, Rabih R ^a   Badaoui, Georges ^a   Sarkis, Antoine ^a   Azar, Mireille ^a   Aydanian, Herminé ^a   Harb, Serge ^a   Achkouty, Guy ^a   Kassab, Roland ^a  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME;

EID: 77955691528     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.03.016     Document Type: Article

References (30)

1. C. Meisinger, J. Baumert, N. Khuseyinova, H. Loewel, and W. Koenig Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population Circulation 112 2005 651 657
2. N. Johnston, T. Jernberg, B. Lagerqvist, A. Siegbahn, and L. Wallentin Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers Am J Cardiol 97 2006 640 645
3. P. Holvoet, A. Mertens, P. Verhamme, K. Bogaerts, G. Beyens, R. Verghaeghe, D. Collen, E. Muls, and F. Van de Werf Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease Arterioscler Thromb Vasc Biol 21 2001 844 848
4. K. Shimada, H. Mokuno, and E. Matsunaga Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease Atherosclerosis 174 2004 343 347
5. D. Steinberg, and A. Lewis Conner Memorial Lecture Oxidative modification of LDL and atherogenesis Circulation 95 1997 1062 1071
6. A. Boullier, D.A. Bird, M.K. Chang, E.A. Dennis, P. Friedman, K. Gilottre-Taylor, S. Hrkk, W. Palinski, O. Quehenberger, P. Shaw, D. Steinberg, V. Terpstra, and J.L. Vitzum Scavenger receptors, oxidized LDL, and atherosclerosis Ann N Y Acad Sci 947 2001 214 223
7. J.A. Berliner, M. Navab, A.M. Fogelman, L.L. Demer, P.A. Edwards, A. Watson, and A.J. Lusis Atherosclerosis: basic mechanisms Oxidation, inflammation and genetics Circulation 91 1995 2488 2496
8. D. Steinberg, S. Parthasarathy, T.E. Carew, J.C. Khoo, and J.L. Witztum Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity N Engl J Med 320 1989 915 924
9. M. Crisby, G. Nordin-Fredriksson, P.K. Shah, J. Yano, J. Zhu, and J. Nilsson Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization Circulation 103 2001 926 933
10. S. Sasaki, N. Kuwahara, K. Kunitomo, S. Harada, T. Yamada, A. Azuma, K. Takeda, and M. Nakagawa Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia Am J Cardiol 89 2002 386 389
11. S. Tsimikas, J.L. Witztum, E.R. Miller, J. Sasiela, M. Szarek, A.G. Olsson, G.G. Schwartz Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Study Investigators High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial Circulation 110 2004 1406 1412
12. C.M. Ballantyne, J. Houri, A. Notarbartolo, L. Melani, L.J. Lipka, R. Suresh, S. Sun, A.P. LeBeaut, P.T. Sager, and E.P. Veltri Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia A prospective, randomized, double-blind trial Circulation 107 2003 2409 2415
13. J.J.P. Kastelein, F. Akdim, E.S.G. Stroes, A.H. Zwinderman, M.L. Bots, A.F.H. Stalenhoef, F.L.J. Visseren, E.J.G. Sijbrands, M.D. Trip, E.A. Stein, D. Gaudet, R. Duivenvoorden, E.P. Veltri, A.D. Marais, E. de Groot ENHANCE Investigators Simvastatin with or without ezetimibe in familial hypercholesterolemia N Engl J Med 358 2008 1431 1443
14. J.L. Fleg, M. Mete, B.V. Howard, J.G. Umans, M.J. Roman, R.E. Ratner, A. Silverman, J.M. Galloway, J.A. Henderson, M.R. Weir, C. Wilson, M. Stylianou, and W.J. Howard Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial J Am Coll Cardiol 52 2008 2198 2205
15. S. Fichtlscherer, C. Schmidt-Lucke, S. Bojunga, L. Rossig, C. Heeschen, S. Dimmeler, and A.M. Zeiher Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patient with CAD: clinical evidence for "pleiotropic" functions of statin therapy Eur Heart J 27 2006 1182 1190
16. M. Settergren, F. Bhm, L. Rydn, and J. Pernow Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease Eur Heart J 29 2008 1753 1760
17. P. Holvoet Oxidized LDL and coronary heart disease Acta Cardiol 59 2004 479 484
18. G. Ndrepepa, S. Braun, N. von Beckerath, J. Mehilli, O. Gorchakova, W. Vogt, A. Shmig, and A. Kastrati Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease Clin Chim Acta 360 2005 178 186
19. M. Kalogirou, V. Tsimihodimos, I. Gazi, T. Filippatos, V. Saougos, A.D. Tselepis, D.P. Mikhailidis, and M. Elisaf Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidemia Curr Med Res Opin 23 2007 1169 1176
20. H.C. Geiss, C. Otto, and K.G. Parhofer Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins Metabolism 55 2006 599 604
21. L. Ose, R. Reyes, A.O. Johnson-Levonas, A. Sapre, D.L. Tribble, and T. Musliner Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques Clin Ther 29 2007 2419 2432
22. D.L. Tribble, M. Farnier, G. Macdonell, I. Perevozskaya, M.J. Davies, B. Gumbiner, and T.A. Musliner Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia Metabolism 57 2008 796 801
23. T. Bjrnheden, A. Babyi, G. Bondjers, and O. Wiklund Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system Atherosclerosis 123 1996 43 56
24. J. De Graaf, H.L.M. Hak-Lemmers, M.P.C. Hectors, P.N.M. Demacker, J.C.M. Hendriks, and A.F.H. Stalenhoef Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects Arterioscler Thromb 11 1991 298 306
25. P.G. Scheffer, G. Bos, H.G.F.M. Volwater, J.M. Dekker, R.J. Heine, and T. Teerlink Associations of LDL size with in vitro oxidizability and plasma levels of in vivo oxidized LDL in type 2 diabetic patients Diabetic Med 20 2003 563 567
26. O. Hussein, L. Minasian, Y. Itzkovich, K. Shestatski, L. Solomon, and J. Zidan Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin Br J Clin Pharmacol 65 2008 637 645
27. D. Li, L. Liu, H. Chen, T. Sawamura, S. Ranganathan, and J.L. Mehta LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells Circulation 107 2003 612 617
28. D. Li, L. Liu, H. Chen, T. Sawamura, and J.L. Mehta LOX-1, an oxidized LDL endothelial receptor, induces CD40/CD40L signaling in human coronary artery endothelial cells Arterioscler Thromb Vasc Biol 23 2003 816 821
29. K. Nishi, H. Itabe, M. Uno, K.T. Kitazato, H. Horiguchi, K. Shinno, and S. Nagahiro Oxidized LDL in carotid plaques and plasma associates with plaque instability Arterioscler Thromb Vasc Biol 22 2002 1649 1654
30. A.J. Taylor, T.C. Villines, E.J. Stanek, P.J. Devine, L. Griffen, M. Miller, N.J. Weissman, and M. Turco Extended-release niacin or ezetimibe and carotid intima-medial thickness N Engl J Med 361 2009 2113 2122